SLT Revolution: Transforming Glaucoma Care
Discover how selective laser trabeculoplasty is reshaping first-line glaucoma treatment with superior long-term results over eye drops.
Selective laser trabeculoplasty (SLT) has emerged as a cornerstone in modern glaucoma management, challenging traditional reliance on topical medications. Recent long-term data from pivotal trials demonstrate its efficacy in lowering intraocular pressure (IOP) and slowing disease progression, potentially shifting clinical guidelines worldwide.
Understanding Glaucoma and the Need for Innovation
Glaucoma affects millions globally, characterized by progressive damage to the optic nerve often due to elevated IOP. Open-angle glaucoma (OAG) and ocular hypertension (OHT) represent the most common forms, where the trabecular meshwork fails to drain aqueous humor effectively. Conventional treatment begins with eye drops, but adherence issues, side effects, and fluctuating IOP control limit their success.
SLT targets melanin-containing cells in the trabecular meshwork using a q-switched Nd:YAG laser at 532 nm. This non-ablative procedure stimulates biological changes that enhance outflow without structural damage, making it repeatable and preserving tissue for future interventions.
Landmark Evidence from the LiGHT Trial
The LiGHT trial, a multicenter randomized controlled study, compared SLT as first-line therapy against eye drops in 718 treatment-naïve patients with OAG or OHT. At six-year follow-up, SLT-first patients showed superior visual field (VF) preservation, with slower mean deviation (MD) progression.
Key outcomes included:
- 70% of SLT-first patients maintained target IOP without drops or surgery at six years.
- Drops-first group had higher rates of progression events and treatment escalations.
- Average IOP was paradoxically higher in SLT group due to adaptive target revisions based on progression.
These findings underscore SLT’s role in consistent IOP control and reduced patient compliance burdens.
Secondary SLT: A Valuable Adjunct After Medications
For patients already on drops, secondary SLT offers medication reduction and IOP stabilization. A post-hoc analysis of 524 patients from an LiGHT extension trial revealed that among 114 stable eyes switched to SLT, 60.5% required no further medical or surgical intervention at 72 months.
| Group | IOP Reduction | Medication-Free at 72 Months | Surgery Needed |
|---|---|---|---|
| Stable Eyes Switched to SLT | 33.9% | 60.5% | Low |
| Uncontrolled Eyes Escalated to SLT | 21.8% (4.6 mm Hg) | 62.5% reached target | 18.7% |
In uncontrolled cases, SLT achieved target IOP in 62.5% without surgery, though advanced disease sometimes necessitated trabeculectomy. This positions secondary SLT as a bridge between medications and surgery.
Direct SLT: Expanding Applications to Angle-Closure
Direct selective laser trabeculoplasty (DSLT) adapts SLT for primary angle-closure glaucoma (PACG), where visualization challenges traditionally limited laser use. Preliminary one-year data from a study on POAG and PACG eyes showed significant IOP reductions and medication decreases, with success rates up to 85.71% in PACG.
DSLT’s efficacy correlates with baseline IOP and pre-treatment drug count, suggesting broader utility in diverse glaucoma subtypes.
Comparative Effectiveness: SLT vs. Traditional Approaches
| Treatment | Initial IOP Reduction | Duration | Repeatability | Side Effects |
|———–|———————|———-|————–|————-|
| SLT | ~30% | 1-5+ years | Yes | Minimal |
| Prostaglandin Drops | ~30% | Ongoing | N/A | Common (e.g., hyperemia) |
| Beta-Blockers | 20-25% | Ongoing | N/A | Systemic risks |
SLT matches pharmacological efficacy while minimizing adherence issues and ocular surface toxicity.
Mechanisms Behind SLT’s Success
SLT induces trabecular meshwork remodeling via macrophage activation, cytokine release, and extracellular matrix changes. This enhances conventional outflow pathways, reducing diurnal IOP fluctuations more effectively than drops. Long-term benefits may stem from sustained biomechanical improvements rather than transient effects.
Patient Selection and Procedure Details
Ideal candidates include mild-to-moderate OAG/OHT patients. Contraindications: angle abnormalities, corneal opacities, or prior extensive laser. Procedure: Outpatient, 10 minutes per eye, topical anesthesia. Post-op: Minimal care, follow-up at 4-6 weeks.
- Success defined as ≥20% IOP drop sustained 6-12 months.
- Repeat SLT viable if initial response fades.
Clinical Implications and Guideline Shifts
UK guidelines now prioritize SLT first-line post-LiGHT. Cost-effectiveness analyses favor laser due to fewer visits and drops. However, confounders like cataract surgery rates warrant cautious interpretation.
Future Directions in Laser Glaucoma Therapy
Ongoing trials explore optimized SLT protocols, combination therapies, and AI-guided targeting. DSLT’s promise in PACG could expand access in angle-closure prevalent regions.
Frequently Asked Questions (FAQs)
What is the typical IOP reduction from SLT?
Around 30% as initial therapy, comparable to top drops.
Can SLT replace eye drops entirely?
In many cases yes, especially first-line; 70% drop-free at six years per LiGHT.
Is SLT safe for repeat treatments?
Yes, low risk due to selective targeting.
How does secondary SLT perform?
Reduces meds in stable eyes (60% drop-free); aids control in uncontrolled (62% target IOP).
Who should consider SLT first?
Treatment-naïve OAG/OHT patients seeking durable, low-maintenance control.
References
- At Six Years Follow-up of LiGHT Trial, SLT Remains Superior First-line Treatment — Review of Optometry. 2024. https://www.reviewofoptometry.com/news/article/at-six-years-followup-of-light-trial-slt-remains-superior-firstline-treatment
- Selective Laser Trabeculoplasty After Medical Treatment for Primary Open-Angle Glaucoma and Ocular Hypertension — JAMA Ophthalmology. 2024-10-10. https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2830476
- Direct Selective Laser Trabeculoplasty: First Results — PMC (Peer-reviewed). 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC11911663/
- Selective Laser Trabeculoplasty (SLT) — Glaucoma Research Foundation (Official). 2023. https://glaucoma.org/treatment/laser/slt
Similar Articles
Read full bio of Sneha Tete
